直肠癌新辅助放化疗患者缺铁性贫血的静脉与口服铁剂补充:随机对照试验研究方案
本研究为开放标签、单中心、平行、优效性随机对照试验,计划纳入94例接受术前放化疗且确诊缺铁性贫血的原发性直肠癌患者,按1:1随机接受静脉或口服铁剂补充,主要终点为从治疗开始至手术入院日血红蛋白恢复正常的患者百分比。
要点
- 研究纳入接受术前放化疗的直肠癌合并缺铁性贫血患者,比较静脉与口服铁剂补充。
- 主要终点为治疗开始至手术入院日血红蛋白恢复正常患者的百分比。
- 计划随机分配94例患者,按年龄和基线血清血红蛋白水平分层。
核心结论
- 本研究是首个在直肠癌新辅助放化疗缺铁患者中探究铁剂补充效果的随机对照试验,预期为铁剂补充的获益提供证据。
研究设计与样本
- 开放标签、单中心、平行、优效性随机对照试验,计划纳入94例接受术前放化疗且确诊缺铁性贫血的原发性直肠癌患者,按1:1随机分配接受静脉或口服铁剂补充,按年龄(>70岁 vs ≤70岁)和基线血清血红蛋白水平(7-10 g/dL vs 10-13 g/dL)分层。
关键数值与推荐
- 主要终点为从治疗开始至手术入院日血红蛋白恢复正常的患者百分比。
- 次要终点包括血清血红蛋白从基线至术后的变化、铁测定参数变化、血红蛋白恢复正常所需时间、所需输血量及术后并发症发生率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Numerous studies have been conducted to manage anemia in surgical patients through iron supplementation as an alternative to blood transfusion. However, patients with locally advanced rectal cancer have often been excluded from these studies, due to their standard treatment involving neoadjuvant chemoradiotherapy. This study aims to evaluate the impact of intravenous versus oral iron supplementation on iron deficiency anemia in patients with rectal cancer receiving preoperative chemoradiotherapy. METHODS: This open-label, single-center, parallel, superiority, randomized trial includes patients with primary rectal cancer who are candidates for preoperative chemoradiotherapy and have confirmed iron-deficiency anemia. A total of 94 patients will be randomly assigned in a 1:1 ratio to receive either intravenous or oral iron supplementation. Stratification factors include age (> 70 vs. ≤ 70 years) and baseline serum hemoglobin levels (7-10 g/dL vs. 10-13 g/dL). The primary endpoint is the percentage of patients achieving normalized hemoglobin levels from the start of treatment to the day of admission for surgery. Secondary endpoints include changes in serum hemoglobin from baseline to postoperatively, changes in iron assay parameters, time needed to hemoglobin normalization, volume of blood transfusions required, and incidence of postoperative complications. DISCUSSION: This study is the first randomized controlled trial investigating the effect of iron supplementation in iron-deficient patients with rectal cancer undergoing neoadjuvant chemoradiotherapy. This trial is expected to provide evidence for the benefits of administering iron supplementation in patients with rectal cancer undergoing neoadjuvant chemoradiotherapy. TRIAL REGISTRATION: Clinical Research Information Service (CRIS) of Republic of Korea, KCT0009260, Registered on March 21, 2024.
引用
- Park HM, Lee J, Lee SY, et al. Intravenous versus oral iron supplementation for iron deficiency anemia in patients with rectal cancer undergoing neoadjuvant chemoradiotherapy: a study protocol for a randomized controlled trial. Trials. 2024. PMID: 39548553. doi:10.1186/s13063-024-08624-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。